Prosight Management, LP
Long book
$609.8M
Q1 2026
Positions
46
Top-10 weight
65%
concentration
Last quarter
+4.6%
SPY +14.8%
Turnover
44%
of book per quarter
Strategy in plain words
auto-generated from filingsProsight Management, LP is a concentrated fundamental stock-picker, specialised in healthcare (96% of the long book), running a $609.8M US long book across 46 positions.
The portfolio is concentrated: the top 10 names carry 65% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: NEKTAR THERAPEUTICS, BOSTON SCIENTIFIC CORP, JANUX THERAPEUTICS INC, PROCEPT BIOROBOTICS CORP, LAKEFRONT BIOTHERAPEUTIC-ADR.
Over the last 9 quarters its long book ran on average 2.9pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-15.5%
Q2 2024
+5.3%
Q3 2024
-5.8%
Q4 2024
-13.7%
Q1 2025
+6.4%
Q2 2025
+27.0%
Q3 2025
+10.1%
Q4 2025
-3.8%
Q1 2026
+4.6%
Sector allocation
Healthcare 93%
Technology 3%
Other 2%
Services media 2%
Long book by quarter
What does Prosight Management, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| NKTR NEKTAR THERAPEUTICS | Healthcare | 735.0K | $52.9M | 8.7% | +32.5% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 795.5K | $49.9M | 8.2% | +278.8% |
| JANX JANUX THERAPEUTICS INC | Healthcare | 3.5M | $49.3M | 8.1% | +48.4% |
| PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 1.9M | $48.6M | 8.0% | +40.9% |
| WGS GENEDX HOLDINGS CORP | Healthcare | 523.5K | $33.6M | 5.5% | +851.8% |
| STTK SHATTUCK LABS INC | Healthcare | 5.0M | $32.2M | 5.3% | +110.1% |
| ADCT ADC THERAPEUTICS SA | Healthcare | 8.3M | $31.1M | 5.1% | -2.1% |
| KURA KURA ONCOLOGY INC | Healthcare | 3.4M | $27.3M | 4.5% | +32.7% |
| ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 76.0K | $25.1M | 4.1% | +344.2% |
| MGTX MEIRAGTX HOLDINGS PLC | Healthcare | 2.6M | $22.8M | 3.7% | -18.1% |
| ALKS ALKERMES PLC | Healthcare | 513.6K | $18.2M | 3.0% | New |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 770.0K | $18.0M | 2.9% | +15.8% |
| VEEV VEEVA SYSTEMS INC-CLASS A | Technology | 86.5K | $15.2M | 2.5% | -4.1% |
| ZYME ZYMEWORKS INC | Healthcare | 539.0K | $13.5M | 2.2% | +1.6% |
| CRNX CRINETICS PHARMACEUTICALS IN | Healthcare | 350.0K | $12.7M | 2.1% | +33.1% |
| CON CONCENTRA GROUP HOLDINGS PAR | Healthcare | 505.8K | $10.8M | 1.8% | -43.2% |
| 430 TERNS PHARMACEUTICALS INC | — | 202.3K | $10.7M | 1.7% | +112.9% |
| PHR PHREESIA INC | Services media | 1.1M | $9.2M | 1.5% | +12.6% |
| OKUR ONKURE THERAPEUTICS INC-A | Healthcare | 2.2M | $8.9M | 1.5% | +163.7% |
| CRBP CORBUS PHARMACEUTICALS HOLDI | Healthcare | 697.1K | $6.5M | 1.1% | +1.9% |
| SDGR SCHRODINGER INC | Healthcare | 510.6K | $5.8M | 1.0% | New |
| EBS EMERGENT BIOSOLUTIONS INC | Healthcare | 639.1K | $5.3M | 0.9% | New |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 180.0K | $5.0M | 0.8% | -71.3% |
| KIDS ORTHOPEDIATRICS CORP | Healthcare | 302.4K | $4.8M | 0.8% | +121.1% |
| IMVT IMMUNOVANT INC | Healthcare | 175.8K | $4.4M | 0.7% | -27.8% |
| ICUI ICU MEDICAL INC | Healthcare | 27.4K | $3.5M | 0.6% | New |
| TECX TECTONIC THERAPEUTIC INC | Healthcare | 79.9K | $2.5M | 0.4% | -66.0% |
| RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 683.9K | $2.4M | 0.4% | -8.1% |
| UPB UPSTREAM BIO INC | Healthcare | 241.1K | $2.2M | 0.4% | New |
| PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.7M | $2.1M | 0.3% | +7.2% |
| OMER OMEROS CORP | Healthcare | 174.8K | $1.8M | 0.3% | New |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 4.0K | $1.8M | 0.3% | New |
| ANTX AN2 THERAPEUTICS INC | Healthcare | 515.8K | $1.8M | 0.3% | New |
| ACET ADICET BIO INC | Healthcare | 250.2K | $1.7M | 0.3% | Held |
| RGNX REGENXBIO INC | Healthcare | 200.0K | $1.7M | 0.3% | New |
| COYA COYA THERAPEUTICS INC | Healthcare | 420.4K | $1.7M | 0.3% | New |
| VKTX VIKING THERAPEUTICS INC | Healthcare | 45.0K | $1.5M | 0.2% | New |
| IRTC IRHYTHM HOLDINGS INC | Healthcare | 10.0K | $1.2M | 0.2% | New |
| TBI TRUEBLUE INC | Services media | 249.1K | $974K | 0.2% | -43.7% |
| IMRX IMMUNEERING CORP - CLASS A | Healthcare | 123.4K | $650K | 0.1% | New |
| PVLA PALVELLA THERAPEUTICS INC | Healthcare | 5.0K | $623K | 0.1% | New |
| NVCR NOVOCURE LTD | Healthcare | 50.4K | $549K | 0.1% | New |
| RNTX REIN THERAPEUTICS INC | Healthcare | 411.6K | $535K | 0.1% | -7.0% |
| TMDX TRANSMEDICS GROUP INC | Healthcare | 5.0K | $497K | 0.1% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 46 | $609.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 38 | $483.9M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 44 | $428.8M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 39 | $410.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 38 | $304.3M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 36 | $361.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 47 | $406.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 46 | $334.6M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 44 | $359.5M | canonical | SEC ↗ |